{"ref-id":"L158","title":"doi:10.1021/cn9000236","url":"http://dx.doi.org/10.1021/cn9000236","parent_key":"BE0000770"}
{"ref-id":"L158","title":"doi:10.1021/cn9000236","url":"http://dx.doi.org/10.1021/cn9000236","parent_key":"BE0000420"}
{"ref-id":"L5512","title":"ChemBL resource, opioid receptors","url":"https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL2095181","parent_key":"BE0000420"}
{"ref-id":"L7820","title":"PharmGKB, Levonorgestrel","url":"https://www.pharmgkb.org/chemical/PA450218","parent_key":"BE0000794"}
{"ref-id":"L7646","title":"FDA Approved Drug Products: Celebrex (celecoxib) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020998s050lbl.pdf","parent_key":"BE0000262"}
{"ref-id":"L12357","title":"FDA Approved Drug Products: Norvir (ritonavir) for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020659s071,%20209512s006,%20022417s023lbl.pdf","parent_key":"BE0004854"}
{"ref-id":"L13676","title":"Therapeutic regimens for the treatment of immunoinflammatory disorders","url":"https://patents.google.com/patent/US20090075955A1/en","parent_key":"BE0000794"}
{"ref-id":"L13682","title":"Composition and method for control and treatment of cutaneous inflammation","url":"https://patents.google.com/patent/US6300326B1/en","parent_key":"BE0000794"}
{"ref-id":"L11398","title":"FDA approved products: Mobic (meloxicam) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020938s024s025,021530s014s015lbl.pdf","parent_key":"BE0000262"}
{"ref-id":"L11398","title":"FDA approved products: Mobic (meloxicam) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020938s024s025,021530s014s015lbl.pdf","parent_key":"BE0000017"}
{"ref-id":"L12435","title":"NIH DailyMed: Suprofen","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8de2c303-5d99-46b6-ad6d-a4caadea3604","parent_key":"BE0000017"}
{"ref-id":"L12435","title":"NIH DailyMed: Suprofen","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8de2c303-5d99-46b6-ad6d-a4caadea3604","parent_key":"BE0000262"}
{"ref-id":"L11416","title":"FDA Approved Drug Products: Actos (pioglitazone) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s049lbl.pdf","parent_key":"BE0000215"}
{"ref-id":"L3450","title":"FDA Approved Drug Products: Invirase (saquinavir mesylate) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021785s024lbl.pdf","parent_key":"BE0004854"}
{"ref-id":"L9227","title":"FDA Approved Drug Products: Prezista (darunavir) oral tablets/suspension","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf","parent_key":"BE0004854"}
{"ref-id":"L161","title":"Link","url":"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515","parent_key":"BE0000163"}
{"ref-id":"L6979","title":"FDA Approved Drug Products: Kalydeco (ivacaftor)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203188s029,207925s008lbl.pdf","parent_key":"BE0001195"}
{"ref-id":"L12651","title":"FDA Approved Products: Gilenya (fingolimod) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022527s031lbl.pdf","parent_key":"BE0002432"}
{"ref-id":"L12651","title":"FDA Approved Products: Gilenya (fingolimod) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022527s031lbl.pdf","parent_key":"BE0008652"}
{"ref-id":"L12651","title":"FDA Approved Products: Gilenya (fingolimod) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022527s031lbl.pdf","parent_key":"BE0009882"}
{"ref-id":"L12651","title":"FDA Approved Products: Gilenya (fingolimod) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022527s031lbl.pdf","parent_key":"BE0009881"}
{"ref-id":"L11232","title":"FDA Approved Products: Sivextro (tedizolid phosphate) tablet and injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf","parent_key":"BE0004800"}
{"ref-id":"L7811","title":"World Health Organization: Butyrfentanyl Critical Review Report","url":"https://www.who.int/medicines/access/controlled-substances/4.2_Butyrfentanyl_CritReview.pdf","parent_key":"BE0000770"}
{"ref-id":"L7811","title":"World Health Organization: Butyrfentanyl Critical Review Report","url":"https://www.who.int/medicines/access/controlled-substances/4.2_Butyrfentanyl_CritReview.pdf","parent_key":"BE0000420"}
{"ref-id":"L1266","title":"EMBL-EBI","url":"https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL2105224","parent_key":"BE0000770"}
{"ref-id":"L1266","title":"EMBL-EBI","url":"https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL2105224","parent_key":"BE0000420"}
{"ref-id":"L1305","title":"Analgesic properties of dexketoprofen trometamol","url":"https://www.researchgate.net/profile/Jean_Sebastien_Walczak/publication/260947943_Analgesic_properties_of_dexketoprofen_trometamol/links/571a523008aee3ddc568f435/Analgesic-properties-of-dexketoprofen-trometamol.pdf","parent_key":"BE0000017"}
{"ref-id":"L1305","title":"Analgesic properties of dexketoprofen trometamol","url":"https://www.researchgate.net/profile/Jean_Sebastien_Walczak/publication/260947943_Analgesic_properties_of_dexketoprofen_trometamol/links/571a523008aee3ddc568f435/Analgesic-properties-of-dexketoprofen-trometamol.pdf","parent_key":"BE0000262"}
{"ref-id":"L1519","title":"Update in anaesthesia","url":"http://e-safe-anaesthesia.org/e_library/03/Paracetamol_Update_2008.pdf","parent_key":"BE0000017"}
{"ref-id":"L1519","title":"Update in anaesthesia","url":"http://e-safe-anaesthesia.org/e_library/03/Paracetamol_Update_2008.pdf","parent_key":"BE0000262"}
{"ref-id":"L2945","title":"Possible Involvement of B5 Opioid Receptor in the Antidepressant-Like Effect of Shuyu Formula in Restraint Stress-Induced Depression-Like Rats","url":"https://www.hindawi.com/journals/ecam/2015/452412/","parent_key":"BE0000770"}
{"ref-id":"L1405","title":"TALNIFLUMATE","url":"https://drugs.ncats.io/ginas/app/substance/7c324c44","parent_key":"BE0000017"}
{"ref-id":"L1405","title":"TALNIFLUMATE","url":"https://drugs.ncats.io/ginas/app/substance/7c324c44","parent_key":"BE0000262"}
{"ref-id":"L2434","title":"Pre-Clinical Demo Orcel","url":"https://www.fda.gov/ohrms/dockets/ac/01/briefing/3771b1_01.pdf","parent_key":"BE0000704"}
{"ref-id":"L2434","title":"Pre-Clinical Demo Orcel","url":"https://www.fda.gov/ohrms/dockets/ac/01/briefing/3771b1_01.pdf","parent_key":"BE0000163"}
{"ref-id":"L2480","title":"Molecular Targets of Aspirin and Cancer Prevention","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090734/","parent_key":"BE0000017"}
{"ref-id":"L2480","title":"Molecular Targets of Aspirin and Cancer Prevention","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090734/","parent_key":"BE0000262"}
{"ref-id":"L1800","title":"Topical Analgesic and Anesthetic Agents Drug Class Review","url":"http://www.health.utah.gov/pharmacy/ptcommittee/files/Criteria%20Review%20Documents/12.13/Topical%20Analgesics%20and%20Anesthetics%20Drug%20Class%20Review.pdf","parent_key":"BE0000017"}
{"ref-id":"L1800","title":"Topical Analgesic and Anesthetic Agents Drug Class Review","url":"http://www.health.utah.gov/pharmacy/ptcommittee/files/Criteria%20Review%20Documents/12.13/Topical%20Analgesics%20and%20Anesthetics%20Drug%20Class%20Review.pdf","parent_key":"BE0000262"}
{"ref-id":"L2613","title":"Dipyrithione inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in macrophages and protects against endotoxic shock in mice","url":"https://www.sciencedirect.com/science/article/pii/S0014579308003347","parent_key":"BE0000005"}
{"ref-id":"L2613","title":"Dipyrithione inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in macrophages and protects against endotoxic shock in mice","url":"https://www.sciencedirect.com/science/article/pii/S0014579308003347","parent_key":"BE0000262"}
{"ref-id":"L1706","title":"Gestrinone","url":"https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1868702","parent_key":"BE0000794"}
{"ref-id":"L1595","title":"Cystic fibrosis news","url":"https://cysticfibrosisnewstoday.com/tezacaftor-vx-661-for-cystic-fibrosis","parent_key":"BE0001195"}
{"ref-id":"L6814","title":"Symdeko FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf","parent_key":"BE0001195"}
{"ref-id":"L1000","title":"ema.europa","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004254/WC500230070.pdf","parent_key":"BE0000710"}
{"ref-id":"L1000","title":"ema.europa","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004254/WC500230070.pdf","parent_key":"BE0002098"}
{"ref-id":"L1000","title":"ema.europa","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004254/WC500230070.pdf","parent_key":"BE0002099"}
{"ref-id":"L1000","title":"ema.europa","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004254/WC500230070.pdf","parent_key":"BE0002097"}
{"ref-id":"L6706","title":"FDA Approved Drug Products: Emflaza (deflazacort) tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf","parent_key":"BE0000794"}
{"ref-id":"L3334","title":"Cancer.gov link","url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/binimetinib","parent_key":"BE0000704"}
{"ref-id":"L11971","title":"FDA Approved Drug Products: Nurtec ODT (rimegepant) orally disintegrating tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf","parent_key":"BE0009009"}
{"ref-id":"L12582","title":"FDA Approved Products: Zeposia (Ozanimod) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf","parent_key":"BE0008652"}
{"ref-id":"L12582","title":"FDA Approved Products: Zeposia (Ozanimod) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf","parent_key":"BE0002432"}
{"ref-id":"L498","title":"UniProt","url":"http://www.uniprot.org/uniprot/P04150","parent_key":"BE0000794"}
{"ref-id":"L499","title":"KEGG","url":"http://www.kegg.jp/dbget-bin/www_bget?hsa:2908","parent_key":"BE0000794"}
{"ref-id":"L9089","title":"FDA Approved Drug Products: Brolucizumab Intravitreal Injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf","parent_key":"BE0000163"}
{"ref-id":"L10842","title":"FDA Approved Drug Products: ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf","parent_key":"BE0000710"}
{"ref-id":"L10926","title":"FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf","parent_key":"BE0009009"}
{"ref-id":"L9395","title":"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf","parent_key":"BE0001195"}
{"ref-id":"L13886","title":"Practical Neurology: Vazegepant, Investigational Drug Being Studied for Migraine, to Enter Phase 2 Trial for COVID-19 Treatment","url":"https://practicalneurology.com/news/vazegepant-investigational-drug-being-studied-for-migraine-to-enter-phase-2-trial-for-covid-19-treatment","parent_key":"BE0009009"}